-
LEOSound - A new device for long-term recording of wheezing and cough in pediatric and adult patients with asthma (during sleep)
Ulrich Koehler, Olaf Hildebrandt, Andreas Weissflog, Angela Zacharasiewicz, Keywan Sohrabi, Niklas Koehler, Volker Gross
Review Article: Clinical Investigation
-
LEOSound - A new device for long-term recording of wheezing and cough in pediatric and adult patients with asthma (during sleep)
Ulrich Koehler, Olaf Hildebrandt, Andreas Weissflog, Angela Zacharasiewicz, Keywan Sohrabi, Niklas Koehler, Volker Gross
Review Article: Clinical Investigation
-
LEOSound - A new device for long-term recording of wheezing and cough in pediatric and adult patients with asthma (during sleep)
Ulrich Koehler, Olaf Hildebrandt, Andreas Weissflog, Angela Zacharasiewicz, Keywan Sohrabi, Niklas Koehler, Volker Gross
Review Article: Clinical Investigation
-
LEOSound - A new device for long-term recording of wheezing and cough in pediatric and adult patients with asthma (during sleep)
Ulrich Koehler, Olaf Hildebrandt, Andreas Weissflog, Angela Zacharasiewicz, Keywan Sohrabi, Niklas Koehler, Volker Gross
Review Article: Clinical Investigation
-
LEOSound - A new device for long-term recording of wheezing and cough in pediatric and adult patients with asthma (during sleep)
Ulrich Koehler, Olaf Hildebrandt, Andreas Weissflog, Angela Zacharasiewicz, Keywan Sohrabi, Niklas Koehler, Volker Gross
Review Article: Clinical Investigation
-
LEOSound - A new device for long-term recording of wheezing and cough in pediatric and adult patients with asthma (during sleep)
Ulrich Koehler, Olaf Hildebrandt, Andreas Weissflog, Angela Zacharasiewicz, Keywan Sohrabi, Niklas Koehler, Volker Gross
Review Article: Clinical Investigation
-
LEOSound - A new device for long-term recording of wheezing and cough in pediatric and adult patients with asthma (during sleep)
Ulrich Koehler, Olaf Hildebrandt, Andreas Weissflog, Angela Zacharasiewicz, Keywan Sohrabi, Niklas Koehler, Volker Gross
Review Article: Clinical Investigation
-
LEOSound - A new device for long-term recording of wheezing and cough in pediatric and adult patients with asthma (during sleep)
Ulrich Koehler, Olaf Hildebrandt, Andreas Weissflog, Angela Zacharasiewicz, Keywan Sohrabi, Niklas Koehler, Volker Gross
Review Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Amantadine and phenytoin: patent protected cases of drug repositioning
Jan M. Keppel Hesselink
Research Article: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
Clinical trial recruitment in the information age
Tom Dorsett, Stella Bennett
Interview: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
AbobotulinumtoxinA for the treatment of upper limb spasticity
Wolfgang H Jost
Clinical Trail Outcomes: Clinical Investigation
-
Ivabradine for the treatment of heart failure
Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ivabradine for the treatment of heart failure
Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ivabradine for the treatment of heart failure
Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ivabradine for the treatment of heart failure
Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ivabradine for the treatment of heart failure
Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ivabradine for the treatment of heart failure
Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ivabradine for the treatment of heart failure
Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ivabradine for the treatment of heart failure
Lynn Elzir, Eileen OMeara, Simon de Denus & Jean-Claude Tardif
Review: Clinical Trail Outcomes: Clinical Investigation
-
Advances in inflammatory bowel diseases 2012
Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Conference Report: Clinical Investigation
-
Advances in inflammatory bowel diseases 2012
Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Conference Report: Clinical Investigation
-
Advances in inflammatory bowel diseases 2012
Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Conference Report: Clinical Investigation
-
Advances in inflammatory bowel diseases 2012
Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Conference Report: Clinical Investigation
-
Advances in inflammatory bowel diseases 2012
Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Conference Report: Clinical Investigation
-
Advances in inflammatory bowel diseases 2012
Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Conference Report: Clinical Investigation
-
Advances in inflammatory bowel diseases 2012
Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Conference Report: Clinical Investigation
-
Advances in inflammatory bowel diseases 2012
Abdo M Saad, Stacy A Kahn, Michele Rubin, David T Rubin
Conference Report: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Noninferiority trials: clinical understandings and misunderstandings
John H Powers,Thomas R Fleming
Editorial: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in rheumatoid arthritis: rationale & clinical evidence
BC Visser, IH Brinkman, MAFJ van de Laar
Review: Clinical Trail Outcomes: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation